TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35179176

Group type: EXPERIMENTAL
Intervention: Healthy Skin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy Lifestyle
Number of subjects: 66
Study: 34053824

Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of people living with HIV)
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of people living with hepatitis B)
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of people living with hepatitis C)
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of people who inject drugs)
Number of subjects: 1632

Group type: EXPERIMENTAL
Intervention: Online stigma reduction intervention (video depicting lived experiences of sex workers)
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1632
Study: 36266559

Group type: EXPERIMENTAL
Intervention: StayFitLonger (SFL) computerized multidomain training program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Active control intervention (basic mobilization exercises and access to video games)
Number of subjects: 120
Study: 33927278

Group type: EXPERIMENTAL
Intervention: Effective CPAP (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham-CPAP (n=12)
Number of subjects: 24
Study: 35830233

Group type: EXPERIMENTAL
Intervention: Technology-assisted telephone intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Traditional telephone intervention
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 33483828

Group type: EXPERIMENTAL
Intervention: Standardized pre-visit laboratory testing before the first visit
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group (no pre-visit testing)
Number of subjects: 594
Study: 32723997

Group type: EXPERIMENTAL
Intervention: Biphasic isophane insulin injection
Number of subjects: 119
Study: 35316078

Group type: EXPERIMENTAL
Intervention: Ultra-mini-percutaneous nephrolithotomy in modified flank free supine position (Group A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Ultra-mini-percutaneous nephrolithotomy in prone position (Group B)
Number of subjects: 122
Study: 33123888

Group type: EXPERIMENTAL
Intervention: Cooking using coal
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cooking using liquefied petroleum gas (LPG) or electricity
Number of subjects: 35

Group type: COMPARATOR
Intervention: Kitchens with range hoods
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Kitchens without range hoods
Number of subjects: 35
Study: 32064832

Group type: EXPERIMENTAL
Intervention: Mouth breathing subjects
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nasal breathing subjects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Older mouth breathing subjects
Number of subjects: 50
Study: 35283116

Group type: EXPERIMENTAL
Intervention: Synthetic ACTH (1 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Betamethasone (6 mg)
Number of subjects: 38
Study: 34546914

Group type: EXPERIMENTAL
Intervention: Smartphone application intervention
Number of subjects: 644

Group type: COMPARATOR
Intervention: Measurement-only control arm
Number of subjects: 644
Study: 36454970

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation - low frequency
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation - high frequency
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Aussie median frequency
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Interferential median frequency
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: High voltage stimulation
Number of subjects: 105
Study: 33438344

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 54

Group type: COMPARATOR
Intervention: ultrathin Descemet stripping automated endothelial keratoplasty (DSAEK)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 54

Group type: COMPARATOR
Intervention: DMEK and DSAEK
Number of subjects: 54
Study: 36262871

Group type: EXPERIMENTAL
Intervention: Low-Temperature Plasma Radiofrequency Ablation (LTPRA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Dynamic-system surgery under nasal endoscope
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups (LTPRA and dissection)
Number of subjects: 106
Study: 33999503

Group type: EXPERIMENTAL
Intervention: Smokeless moxibustion (SLM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smoke moxibustion (SM)
Number of subjects: 60
Study: 33513653

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study: 32150492

Group type: EXPERIMENTAL
Intervention: Epinephrine HFA MDI at doses above 125 μg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine HFA MDI at doses 125-250 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine CFC MDI (220 μg/inhalation)
Number of subjects: 0
Study: 36259487

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided platelet-rich plasma (PRP) injection combined with drugs
Number of subjects: 80

Group type: COMPARATOR
Intervention: Drugs alone (Control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PRP injection combined with drugs
Number of subjects: 80
Study: 33884840

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 0
Study: 33441384

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 1357

Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Number of subjects: 1357

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1357
Study: 33568603

Group type: EXPERIMENTAL
Intervention: Verbal information (Group I)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Video of surgery on manikins (Group II)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Video of surgery on a real patient (Group III)
Number of subjects: 270
Study: 36100118

Group type: EXPERIMENTAL
Intervention: AGV-Ologen
Number of subjects: 33

Group type: COMPARATOR
Intervention: AGV
Number of subjects: 33
Study: 32149709

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold (BRS)
Number of subjects: 60
Study: 35261115

Group type: EXPERIMENTAL
Intervention: Active TMS (left and right VLPFC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Active TMS (right VLPFC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham TMS (vertex)
Number of subjects: 120
Study: 32240866

Group type: EXPERIMENTAL
Intervention: Multi-electrode mapping (MEM)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional activation mapping (CAM)
Number of subjects: 114
Study: 36057163

Group type: EXPERIMENTAL
Intervention: Pediatric-adult transition program
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Healthcare professionals' involvement
Number of subjects: 12
Study: 33845626

Group type: EXPERIMENTAL
Intervention: CO-OP + OPC (Cognitive Orientation to daily Occupational Performance Approach with Occupational Performance Coaching)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CO-OP (Cognitive Orientation to daily Occupational Performance Approach)
Number of subjects: 0
Study: 32081787

Group type: EXPERIMENTAL
Intervention: T cell receptor (TCR) repertoire analysis in patients with steroid nonresponsive aGVHD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of Vβ20 and Vβ29
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCR repertoire analysis in patients with shared HLA mismatch
Number of subjects: 0
Study: 35678177

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (night administration)
Number of subjects: 118
Study: 32100190

Group type: EXPERIMENTAL
Intervention: Endogenous estradiol
Number of subjects: 155
Study: 35428609

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg/kg on day 1, followed by 80 mg/kg on days 2 and 3, plus granisetron 3 mg/m2 on day 1 and dexamethasone on days 1 to 3
Number of subjects: 120

Group type: COMPARATOR
Intervention: Aprepitant 125 mg/kg on day 1 and placebo on days 2 and 3, plus granisetron 3 mg/m2 on day 1 and dexamethasone on days 1 to 3
Number of subjects: 120
Study: 32537707

Group type: EXPERIMENTAL
Intervention: Multi-component training (including dual-task, dynamic balance, endurance and strength exercises) for 16 weeks (twice per week for 45–60 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 24
Study: 35732849

Group type: EXPERIMENTAL
Intervention: Remifentanil (R)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 68
Study: 34627582

Group type: EXPERIMENTAL
Intervention: Sildenafil and ambrisentan combination therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sildenafil monotherapy
Number of subjects: 27
Study: 35567889

Group type: EXPERIMENTAL
Intervention: Probiotic (Vivomix 112 billion, one capsule a day for 16 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 35468153

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG seropositivity testing
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Vaccination status
Number of subjects: 459

Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Healthcare role
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Workplace setting
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: ICU vs. ambulatory clinic
Number of subjects: 459
Study: 32911306

Group type: EXPERIMENTAL
Intervention: teriflunomide 14 mg
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: teriflunomide 7 mg/14 mg
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: teriflunomide 14 mg/14 mg
Number of subjects: 751

Group type: COMPARATOR
Intervention: placebo/teriflunomide 14 mg
Number of subjects: 751
Study: 36454520

Group type: EXPERIMENTAL
Intervention: Drug-related readmission within 12 months post-discharge
Number of subjects: 2637

Group type: EXPERIMENTAL
Intervention: Potentially preventable drug-related revisits
Number of subjects: 2637
Study: 33305744

Group type: EXPERIMENTAL
Intervention: Group RD: 30 ml of 0.5% Ropivacaine + 0.75 mcg/kg Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group RS: 30 ml of 0.5% Ropivacaine + 1 ml Normal Saline
Number of subjects: 60
Study: 35791646

Group type: EXPERIMENTAL
Intervention: DBPR108 + metformin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 150
Study: 33563040

Group type: EXPERIMENTAL
Intervention: fruquintinib
Number of subjects: 416
Study: 32787896

Group type: EXPERIMENTAL
Intervention: 8-week home-based telerehabilitation virtual reality (VR) program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional therapy focusing on task-related upper-limb treatments
Number of subjects: 24
Study: 35792882

Group type: EXPERIMENTAL
Intervention: VGT-309
Number of subjects: 2
Study: 34269894

Group type: EXPERIMENTAL
Intervention: Automatic/systematic CR referral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician CR encouragement at the bedside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupervised program models
Number of subjects: 0
Study: 35944235

Group type: EXPERIMENTAL
Intervention: < 3.0 MET-h/wk
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: ≥ 18.0 MET-h/wk
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: 0.0 h/wk (light to moderate intensity)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: ≥ 1.5 h/wk (light to moderate intensity)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: 0.0 h/wk (vigorous intensity)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: ≥ 1.0 h/wk (vigorous intensity)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: < 1.0 h/wk (brisk walking)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: ≥ 3.0 h/wk (brisk walking)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: 0.0 h/wk (muscle strengthening)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: ≥ 0.5 h/wk (muscle strengthening)
Number of subjects: 1696
Study: 32929783

Group type: EXPERIMENTAL
Intervention: Burst spinal cord stimulation (SCS)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tonic spinal cord stimulation (SCS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both modes (burst and tonic)
Number of subjects: 69
Study: 32631447

Group type: EXPERIMENTAL
Intervention: 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) preparation, titrated doses ranging from 2.5 mg/2.5 mg to 30 mg/30 mg per day, administered as an oral solution for a total of 4 weeks (2 weeks titration + 2 weeks stable dose).
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) preparation.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (oral solution).
Number of subjects: 150
Study: 32572862

Group type: EXPERIMENTAL
Intervention: Anterior POEM
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Posterior POEM
Number of subjects: 111

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 111
Study: 35667000

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Well-Rested (WR)
Number of subjects: 47
Study: 32106733

Group type: EXPERIMENTAL
Intervention: ≥ 75% group (greater initial migration)
Number of subjects: 39

Group type: COMPARATOR
Intervention: < 75% group (less initial migration)
Number of subjects: 39
Study: 36164152

Group type: EXPERIMENTAL
Intervention: Isatuximab plus Carfilzomib and Dexamethasone (Isa-Kd)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Carfilzomib and Dexamethasone (Kd)
Number of subjects: 302
Study: 32538212

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake
Number of subjects: 217
Study: 35689421

Group type: EXPERIMENTAL
Intervention: TDF® Blu Voile Sunscreen
Number of subjects: 39
Study: 33676886

Group type: EXPERIMENTAL
Intervention: Personalized digital and human direct oral anticoagulant adherence intervention (medication management smartphone app, daily app-based reminders, adaptive text messaging, and phone-based counseling for severe nonadherence)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Personalized digital and human direct oral anticoagulant adherence intervention
Number of subjects: 139
Study: 35527666

Group type: EXPERIMENTAL
Intervention: Daily oral LTRA 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Step-up medium dose of ICS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 32838353

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Arbidol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (no antiviral medication)
Number of subjects: 86
Study: 36175831

Group type: EXPERIMENTAL
Intervention: AUD$10 unconditional incentive
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: AUD$20 unconditional incentive
Number of subjects: 238

Group type: COMPARATOR
Intervention: Comparison of response rates between AUD$10 and AUD$20 groups
Number of subjects: 238
Study: 34127032

Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation using G-EO system (30 min traditional therapy + 20 min robotic treatment)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Traditional rehabilitation program (50 min traditional therapy)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation using G-EO system
Number of subjects: 152

Group type: COMPARATOR
Intervention: Traditional rehabilitation program
Number of subjects: 152
Study: 32805198

Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for systolic blood pressure (GRSSBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for diastolic blood pressure (GRSDBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for mean arterial pressure (GRSMAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for pulse pressure (GRSPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic risk scores (GRS) for hypertension (GRSHTN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined genetic risk scores (GRScomb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional risk factors
Number of subjects: 0
Study: 35337743

Group type: EXPERIMENTAL
Intervention: Landiolol (0.5, 1, 2, 5, and 10 μg/kg/min)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 58
Study: 35466156

Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg/day × 4 days)
Number of subjects: 420

Group type: COMPARATOR
Intervention: No pitavastatin (Control group)
Number of subjects: 420
Study: 34986478

Group type: EXPERIMENTAL
Intervention: Massage Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aromatherapy
Number of subjects: 0
Study: 33957724

Group type: EXPERIMENTAL
Intervention: propofol-ketamine (Group K; n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: propofol-fentanyl (Group F; n = 50)
Number of subjects: 100
Study: 32568935

Group type: EXPERIMENTAL
Intervention: Lay patient navigation intervention (5 home visits over 3 months)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Lay patient navigation intervention
Number of subjects: 112
Study: 36005883

Group type: EXPERIMENTAL
Intervention: EPA 4 g/d
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: EPA 1 g/d
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: EPA 2 g/d
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 32145103

Group type: EXPERIMENTAL
Intervention: Muscular fitness
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Speed-agility
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Overall fitness score
Number of subjects: 201
Study: 33392769

Group type: EXPERIMENTAL
Intervention: Pre-emptive doxycycline prophylaxis for anti-EGFR-related skin toxicity
Number of subjects: 226
Study: 32070283

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (10 l/min)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 160
Study: 33874750

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401

Group type: EXPERIMENTAL
Intervention: SGLT2i (pooled from 4 CVOTs)
Number of subjects: 4401
Study: 32312112

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE)
Number of subjects: 1672
Study: 35109841

Group type: EXPERIMENTAL
Intervention: Quinine (20 mg/kg/day) plus Clindamycin (20 mg/kg/day) for 3 days
Number of subjects: 384

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (artemether 20 mg, lumefantrine 120 mg) for 3 days
Number of subjects: 384
Study: 33736706

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 88

Group type: COMPARATOR
Intervention: Balance and tone training (active control)
Number of subjects: 88
Study: 35410590

Group type: EXPERIMENTAL
Intervention: PartoMa intervention (co-created clinical practice guidelines and low-dose, high-frequency training)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PartoMa intervention
Number of subjects: 5
Study: 32316790

Group type: EXPERIMENTAL
Intervention: Gentle human touch during endotracheal suctioning
Number of subjects: 34

Group type: COMPARATOR
Intervention: No intervention (suctioning without gentle human touch)
Number of subjects: 34
Study: 33431052

Group type: EXPERIMENTAL
Intervention: High-dose saccharin supplementation (administered in capsules twice daily for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose saccharin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: T1R2-KO mice (compared to WT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactisole (STR inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saccharin with lactisole
Number of subjects: 0
Study: 32004499

Group type: EXPERIMENTAL
Intervention: Type-IV resistant starches (RS4s), specifically crystalline and phosphate cross-linked starch structures, administered at a dose of 35 g/day.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type-IV resistant starches (RS4s) at a dose of 35 g/day.
Number of subjects: 0
Study: 35991892

Group type: EXPERIMENTAL
Intervention: Intravenous hydromorphone PCA (0.05 mg/h with 0.2 mg on-demand)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Intravenous hydromorphone PCA
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intramuscular pethidine (50 mg as required)
Number of subjects: 77
Study: 33422288

Group type: EXPERIMENTAL
Intervention: Positive communication behaviour during medical handover
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (standardised handover without positive communication)
Number of subjects: 64
Study: 33769373

Group type: EXPERIMENTAL
Intervention: Early transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vasoactive therapy (octreotide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thromboelastography-guided approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-expanding metallic stents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEG-based transfusion strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study: 34362816

Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 25

Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 25
Study: 36231767

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ischemic Compression (IC)
Number of subjects: 80